Trials / Completed
CompletedNCT05633862
A Study in Healthy Chinese People to Test How Different Doses of BI 1015550 Are Taken up in the Body
Pharmacokinetics, Safety and Tolerability of Doses of BI 1015550 in Healthy Chinese Male and Female Subjects (Open-label, Parallel Group Design)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The main objectives of this trial are to investigate pharmacokinetics, safety and tolerability of BI 1015550 in Chinese healthy male and female subjects following administration of single doses.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BI 1015550 | A single film-coated tablet BI 1015550 taken orally after an overnight fast of at least 10 hours. |
Timeline
- Start date
- 2023-01-13
- Primary completion
- 2023-03-16
- Completion
- 2023-03-17
- First posted
- 2022-12-01
- Last updated
- 2025-11-28
- Results posted
- 2025-11-28
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05633862. Inclusion in this directory is not an endorsement.